COR vs ELAN vs ICCC Stock Comparison

Cencora, Elanco Animal Health and Immucell Prices as of Nov 13, 2026 Peers: Industry group
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
5 wins
ICCC Immucell Corp /De/
$10.75 0.0% 1M +77.7% 1Y
Market cap
$102.43M
P/E
54.5x
Revenue (TTM)
$33.21M
Div. yield
–
Animal Health Healthcare
6 wins

Head to Head

11 decided of 12

Immucell leads on 6 of the 12 questions below (Immucell 6, Cencora 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCORELANICCCLeader
Larger companyMarket capitalisation $69.10B $13.25B $102.43M COR
Cheaper on earningsLower P/E, profitable companies only 22.6x -90.2x 54.5x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.8x 23.7x — COR
Faster revenue growthRevenue growth, trailing twelve months +5.0% +12.1% +19.6% ICCC
More profitableNet margin, trailing twelve months — -2.9% 5.7% ICCC
Better return on capitalReturn on invested capital — 6.9% 11.7% ICCC
Less leveragedLower net debt / EBITDA — 2.3x 0.0x ICCC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -1.8% +21.8% +77.7% ICCC
Better 5-year returnAnnualised price return, 5 years +23.4%/yr -4.1%/yr +3.1%/yr COR
Less volatileAnnualised volatility, 1 year 33.4% 43.4% 50.5% COR
Higher overall scoreMean of the five percentile scores vs peers 56/100 69/100 80/100 ICCC

Percentile Scorecard

CORELANICCC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCORELANICCC
Valuation 54 #13 of 27 92 #52 of 660 91 #63 of 660
Growth 64 #10 of 26 67 #208 of 619 88 #75 of 619
Profitability 64 #10 of 26 85 #90 of 595 90 #62 of 595
Financial Health – 31 #473 of 683 57 #298 of 683
Shareholder Returns 41 #11 of 18 73 #126 of 459 75 #115 of 459
Overall 56 69 80
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • ELAN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ICCC ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCORELANICCCSPY
1 month +6.8%+18.8%0.0% -2.0%
3 months +14.4%+13.2%+7.0% -2.8%
6 months +39.3%+34.9%+20.5% +2.0%
Year to date +6.3%+18.4%+74.8% +10.6%
1 year -1.8%+21.8%+77.7% +12.2%
3 years +84.7%+136.2%+102.8% +68.1%
3 years, per year +22.7%+33.2%+26.6% +18.9%
5 years +186.4%-18.9%+16.6% +61.4%
5 years, per year +23.4%-4.1%+3.1% +10.1%
10 years +354.9%—+108.3% +248.5%
10 years, per year +16.4%—+7.6% +13.3%

Risk

MeasureCORELANICCCSPY
Volatility, 1Y 33.4%43.4%50.5% 13.6%
Downside volatility, 1Y 40.0%43.7%47.9% 13.9%
Beta vs S&P 500, 1Y 0.051.320.45 1.00
Return / volatility, 1Y -0.050.501.54 0.90
Max drawdown, 5Y -32.6%-75.0%-67.0% -25.4%
From 52-week high -4.2%-0.2%-8.3% -3.2%
52-week high $374.75$26.84$11.72 $779.14
52-week low $252.74$19.80$4.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCORELANICCC
P/E now vs peer median 22.6xmedian 25.2x -91.1xmedian 17.0x 52.0xmedian 17.0x
P/S now vs peer median 0.2xmedian 0.4x 2.6xmedian 8.4x 2.9xmedian 8.4x
EV/EBITDA now vs peer median —median 14.5x 11.8xmedian 14.6x 14.0xmedian 14.6x
P/FCF now vs peer median 14.5xmedian 16.5x 32.8xmedian 19.0x 18.1xmedian 19.0x
P/B now vs peer median 18.6xmedian 2.7x 2.0xmedian 2.0x 3.0xmedian 2.0x
PEG now vs peer median —median 1.72 -1.82median 0.43 1.68median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCORELANICCC
Revenue $337.40B $5.15B $33.21M
Gross profit $13.87B $2.89B $13.56M
Operating income $3.93B $720.00M $4.80M
Net income $3.51B -$147.00M $1.88M
Free cash flow – $408.00M $5.40M
R&D – $381.00M $1.37M
EPS (diluted) – $-0.29 $0.20
Cash & equivalents $4.88B $465.00M $7.91M
Total debt – $3.71B $7.90M
Shares (diluted) 193.94M 506.50M 9.30M
Enterprise value $69.10B $11.29B $75.03M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCORELANICCC
P/E 22.6x -91.1x 52.0x
P/FCF 14.5x 32.8x 18.1x
P/Operating cash flow 14.3x 21.8x 12.5x
P/S 0.2x 2.6x 2.9x
P/B 18.6x 2.0x 3.0x
P/Tangible book 18.6x 3.7x 3.0x
EV/EBITDA – 11.8x 14.0x
EV/EBIT – 23.1x 20.3x
EV/Revenue 0.2x 3.2x 2.9x
EV/FCF – 40.8x 18.1x
EV/Operating cash flow 14.3x 27.1x 12.5x
PEG (3Y EPS CAGR) – -1.82 1.68

Growth

14 metrics
MetricCORELANICCC
Revenue growth (1Y) 5.0% 12.1% 19.6%
Revenue CAGR (3Y) 8.8% 5.6% 26.8%
Gross profit growth (1Y) 20.8% 14.6% 19.3%
Gross profit CAGR (3Y) 15.7% 4.9% 55.5%
Operating income growth (1Y) 49.5% 20.6% 106.3%
Operating income CAGR (3Y) 18.9% 41.2% 40.2%
Net income growth (1Y) 124.0% -508.3% -19.1%
Net income CAGR (3Y) 26.3% 49.5% 32.0%
EPS growth (1Y) – -500.5% -21.3%
EPS CAGR (3Y) – 50.0% 31.0%
Operating cash flow growth (1Y) 23.6% -2.4% 293.6%
Operating cash flow CAGR (3Y) 7.0% 69.1% 51.7%
Free cash flow growth (1Y) – 10.9% 655.1%
Free cash flow CAGR (3Y) – 117.8% 37.9%

Profitability

14 metrics
MetricCORELANICCC
Gross margin – 56.2% 40.8%
EBITDA margin – 27.5% 21.1%
Operating margin – 14.0% 14.5%
Pretax margin – -1.8% 5.8%
Net margin – -2.9% 5.7%
FCF margin – 7.9% 16.3%
Operating cash flow margin 1.4% 11.9% 23.6%
Return on equity 101.2% -2.2% 5.9%
Return on assets 4.1% -1.1% 4.0%
Return on invested capital – 6.9% 11.7%
Return on capital employed – 6.2% 11.3%
Asset turnover 3.9x 0.4x 0.7x
Cash conversion (OCF / net income) 1.4x -4.2x 4.2x
Stock comp / revenue – 1.5% 2.6%

Financial Health

11 metrics
MetricCORELANICCC
Debt / assets – 27.8% 16.5%
Debt / equity – 0.6x 0.2x
Net debt / EBITDA – 2.3x 0.0x
Debt / FCF – 9.1x 1.5x
Liabilities / assets – 50.3% 31.7%
Equity / assets 4.2% 49.7% 68.3%
Interest coverage – 2.8x 12.2x
Current ratio 0.9x 2.1x 4.6x
Quick ratio – 0.9x 2.4x
Cash ratio – 0.3x 1.7x
Altman Z-score – 1.72 5.00

Shareholder Returns

7 metrics
MetricCORELANICCC
Dividend yield 0.9% – –
Net buyback yield – -0.3% -0.2%
Shareholder yield 0.9% -0.3% -0.2%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCORELANICCC
Forward P/E 18.8xFY2027 23.7xFY2026 –
EPS, next fiscal year $19.07FY2027 $1.13FY2026 –
EPS growth, next FY +6.1%FY2027 +20.2%FY2026 –
EPS growth, the year after +17.4% +22.1% –
Revenue, next fiscal year $328.27BFY2027 $4.82BFY2026 –
Revenue growth, next FY -2.7%FY2027 +2.4%FY2026 –
Revenue growth, the year after +19.1% +19.4% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCORELANICCC
Held by institutions 94.7% 100.0% 15.0%
Institutions holding 1,345 526 32
Change in shares held, QoQ +15.7% +4.4% -2.6%
Institutions buying 542 246 15
Institutions selling 612 211 7
Buyers to sellers 0.89 1.17 2.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CORELANICCC
COR 1.00 -0.03 0.05
ELAN -0.03 1.00 -0.03
ICCC 0.05 -0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, COR, ELAN and ICCC?

Cencora (COR) is the largest by market capitalisation: Cencora (COR) $69.10B, Elanco Animal Health (ELAN) $13.25B, Immucell (ICCC) $102.43M.

Which stock is cheaper, COR, ELAN and ICCC?

Cencora (COR) trades on the lowest price-to-earnings ratio (Cencora (COR) 22.6x, Elanco Animal Health (ELAN) -90.2x, Immucell (ICCC) 54.5x). On next year's consensus earnings, Cencora (COR) is cheapest (Cencora (COR) 18.8x, Elanco Animal Health (ELAN) 23.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Immucell (ICCC) grew revenue fastest over the trailing twelve months: Cencora (COR) +5.0%, Elanco Animal Health (ELAN) +12.1%, Immucell (ICCC) +19.6%.

Which company is more profitable?

Immucell (ICCC) has the highest net margin (Elanco Animal Health (ELAN) -2.9%, Immucell (ICCC) 5.7%). On return on invested capital, Immucell (ICCC) leads (Elanco Animal Health (ELAN) 6.9%, Immucell (ICCC) 11.7%).

Which stock has performed better?

Over the past year Immucell (ICCC) returned the most: Cencora (COR) -1.8%, Elanco Animal Health (ELAN) +21.8%, Immucell (ICCC) +77.7%. Over five years, Cencora (COR) compounded fastest (Cencora (COR) +23.4%/yr, Elanco Animal Health (ELAN) -4.1%/yr, Immucell (ICCC) +3.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Cencora (COR) 33.4%, Elanco Animal Health (ELAN) 43.4%, Immucell (ICCC) 50.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, COR, ELAN and ICCC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Immucell (ICCC) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.